Lataa...
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B...
Tallennettuna:
| Julkaisussa: | Leukemia |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Nature Publishing Group UK
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7862069/ https://ncbi.nlm.nih.gov/pubmed/33122850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-01072-6 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|